Published in JAMA Network Open · View the paper (DOI)
A comparative effectiveness study found that liraglutide, semaglutide, and dulaglutide have similar risks for kidney and cardiovascular outcomes in veterans with type 2 diabetes. Head-to-head trials are needed to confirm these findings.
Coverage from 2 institutions